A5083222111- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Restless Legs Syndrome Research
- Autism Spectrum Disorder Research
- Botulinum Toxin and Related Neurological Disorders
- High Altitude and Hypoxia
- Acute Ischemic Stroke Management
- Dysphagia Assessment and Management
- Genetic Neurodegenerative Diseases
- Venous Thromboembolism Diagnosis and Management
- Diabetes Treatment and Management
- Cerebrovascular and Carotid Artery Diseases
- Epilepsy research and treatment
- Climate Change and Health Impacts
- Prion Diseases and Protein Misfolding
- Respiratory Support and Mechanisms
- Nuclear Receptors and Signaling
- Health Systems, Economic Evaluations, Quality of Life
- Drug Transport and Resistance Mechanisms
- Child Nutrition and Feeding Issues
- Intracerebral and Subarachnoid Hemorrhage Research
- Neurological diseases and metabolism
- Alcohol Consumption and Health Effects
- Pharmacological Effects and Toxicity Studies
- Renal function and acid-base balance
Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș
2014-2025
Spitalul Clinic Judetean de Urgenta Târgu Mureş
2021-2024
Baranya Megyei Kórház
2020
ABSTRACT Levodopa is effective for the motor symptoms of Parkinson's disease (PD), but associated with fluctuations and dyskinesia. Many patients require add‐on therapy to improve without exacerbating The objective this Phase III, multicenter, double‐blind, placebo‐controlled, parallel‐group study was evaluate efficacy safety safinamide, an α‐aminoamide dopaminergic nondopaminergic mechanisms, as l ‐dopa in treatment PD fluctuations. Patients were randomized oral safinamide 100 mg/day (n =...
Abstract In a 6‐month double‐blind, placebo‐controlled study of Parkinson's disease patients with motor fluctuations, safinamide 50 and 100 mg/d significantly increased ON‐time without increasing dyskinesia. Further long‐term use in these was evaluated over an additional 18 months. Patients continued on their randomized placebo, 50, or safinamide. The primary endpoint change Dyskinesia Rating Scale total score during 24 Other efficacy endpoints included troublesome dyskinesia, changes...
Background: For Parkinson disease (PD) patients who have been diagnosed with advanced that can no longer be effectively controlled optimized oral or transdermal medications, a range of device-aided therapies (DAT) are available, comprising either deep brain stimulation infusion providing continuous dopaminergic stimulation. Levodopa–entacapone–carbidopa intestinal gel (LECIG) is the latest DAT for PD (APD) was approved in Romania 2021. Study Question: What experience to date real-world...
ABSTRACT Background Levodopa‐carbidopa intestinal gel (LCIG) is administered directly to the small intestine of patients with advanced Parkinson's disease (APD) help maintain stable plasma levodopa levels. Objective The objective this study was investigate effect LCIG in reducing polypharmacy for treatment APD. Methods COmedication Study assessing Mono‐ and cOmbination therapy levodopa‐carbidopa inteStinal (COSMOS) a large, real‐world, multinational observational investigating comedication...
Levodopa–entacapone–carbidopa intestinal gel infusion is a relatively new treatment option for advanced Parkinson’s disease. We aimed to describe and analyze the characteristics of de novo levodopa–entacapone–carbidopa therapy in 20 consecutive patients with assessed profile motor complications by evaluating following: fluctuations, dyskinesias, freezing phenomenon at baseline (before testing period) before discharge. The significantly reduced duration daily hours spent off time compared...
Bevezetés: Előrehaladott Parkinson-kórban az oralisan, illetve transdermalisan adagolt dopaminerg szerek már nem elég hatékonyak, és jelentős mellékhatással bírnak, ezért szükség lehet a folyamatos stimuláció elvén alapuló eszközös terápiák valamelyikére. Célkitűzés: Célunk volt összehasonlítani levodopa-entakapon-karbidopa intestinalis géllel kezelt, előrehaladott Parkinson-kóros betegeink klinikai paramétereit kezelés megkezdése előtt közvetlenül klinikáról való elbocsátáskor. Módszer:...
Introduction: The management of sedation during percutaneous endoscopic gastrojejunostomy (PEG-J) placement in patients with advanced Parkinson’s disease (PD) is challenging due to the complex interactions between PD treatment, anesthetic agents, and disease’s motor non-motor symptoms. This study evaluates effectiveness safety a target-controlled infusion (TCI) propofol protocol context PEG-J patients. Materials Methods: prospective included 169 diagnosed (Hoehn Yahr stages 4 5) who...
Levodopa-entacapone-carbidopa intestinal gel (LECIG) was introduced in 2018 as a device-aided therapy for advanced Parkinson's disease (PD). The ELEGANCE study (NCT05043103) is gathering real-world data on long-term efficacy, safety and patient-reported outcomes with LECIG from 13 European countries. This article reports the planned interim analysis. enrolled patients prescribed part of routine clinical care. We evaluated at V1 before starting treatment (in seven were obtained...
In addition to the classically accepted pathophysiological features of Alzheimer’s disease (AD), increasing attention is paid role insulin-resistant state central nervous system. Glucagon-like peptide-1 receptor (GLP-1R) agonism demonstrated neuroprotective consequences by mitigating neuroinflammation and oxidative damage. The present review aims offer a comprehensive overview properties GLP-1R agonists (GLP-1RAs), with particular focus on experimental animal models AD. Ameliorated amyloid-β...
As hemorrhagic transformation (HTr) is a frequent complication and can worsen the outcome of acute ischemic stroke, our aim was to assess risk factors HTr. Using database neuropathological laboratory, 245 consecutive stroke patients were analyzed. An exploratory logistic regression procedure carried out find best multiple model identifying associated with The autopsy revealed infarct in 175 (71%) HTr 70 (29%) patients. Mean age 71.5 ± 11.4 years (mean SD) 74.8 10.2 SD), respectively....
Chronic treatment with oral levodopa is associated an increased frequency of motor complications in the late stages Parkinson's disease (PD). Continuous administration levodopa–carbidopa intestinal gel (LCIG—Duodopa®, Abbott Laboratories), which has been available Romania since 2009, represents option for treating patients advanced PD. Our primary objective was to report changes after initiation LCIG therapy. The secondary objectives were as follows: determine impact therapy on daily dose...
Background: There is insufficient data in the literature regarding real-life, daily clinical practice evaluation of patients with advanced Parkinson's disease (APD). We are not sure what upper limit dopaminergic medication, especially levodopa (LD) dosage, and how it influenced by access suitability to various add-on device-aided therapies (DAT). Objective: This retrospective study explored profile APD that were considered systematically evaluated for DAT. Methods: analyzed from 311...
OBSERVE-PD was a cross-sectional, multicountry, observational study conducted in 128 Movement Disorders Centers (MDCs) 18 countries. Overall, the enrolled 2615 patients. The aim to determine proportion of patients with advanced Parkinson's disease (APD) versus non-APD from MDCs and uncover clinical burden APD, as well correlation between overall assessment APD several indicators APD. stage severity were assessed by investigators using their judgement. Data collected during single visit...
In patients older than 70 years there is no valid alternative to progressively introduced substitution therapy. The antiparkinsonian drugs in the last decade treat Parkinson's disease, especially its early phases, promised a comparable efficacy reducing symptoms levodopa. younger and/or with mild we hoped delay motor complications by postponing start of levodopa While these assumptions may not be true for all patients, probably most important current challenge optimal starting moment aim...
Parkinson's disease (PD) is the second most common progressive neurodegenerative disease. In advanced stages, continuous delivery of levodopa (LD) as levodopa-carbidopa intestinal gel (LCIG) has demonstrated significant improvement motor and nonmotor complications patients' quality life (QoL). Despite growing global experience with this treatment, anumber unsolved practical issues remain, currently, data on reasons that can lead to discontinuation LCIG are scarce.In present study, we aimed...
IntroductionPatients with advanced Parkinson's disease (APD) commonly experience motor and nonmotor symptoms (NMS) associated functional limitations decreased quality of life. We compared outcomes in patients APD receiving 24- versus 16-h levodopa-carbidopa intestinal gel (LCIG).MethodsData from COSMOS, a large, real-world, retrospective cross-sectional, observational study on LCIG comedication were obtained medical records single patient visit for infusion. Changes baseline evaluated...
There is relatively few data regarding the usage of dopaminagonists for treatment Parkinson's disease; furthermore, there are no publications Central- and Eastern-European countries. The aim study was to evaluate use dopamine agonists as a therapeutic option amongst disease patients admitted Neurological Clinics Tîrgu Mures during last 15 years.In our we investigated all treated at clinics between 1st January 2003 31st December 2017. We analyzed particularities agonists' based on...
Abstract The primary objective of this trial (SP1042; NCT02582866) was to assess long‐term safety and tolerability lacosamide monotherapy (200‐600 mg/day) in adults with focal (partial‐onset) seizures or generalized tonic‐clonic (without clear origin). This Phase III, long‐term, open‐label, multicenter, follow‐up enrolled patients epilepsy who were taking in, completed, the previous double‐blind (SP0994; NCT01465997). Primary outcomes treatment‐emergent adverse events (TEAEs),...
Selective monoamine oxidase B inhibitors have an accurate place in therapeutical strategy of Parkinsons's disease. In the early stages disease, especially younger patients with milder symptoms, introduction levodopa substitution could be efficacious delaying; advanced they are mainly used to treat motor complications, as adjunct levodopa.The evaluation strategies neurology clinics Tirgu Mures County Emergency Clinical Hospital order define role inhibitors.This retrospective study includes...
Abstract: Introduction: The motor and non-motor complications of Parkinson’s disease impair the patients’ quality life limit therapeutical options. There are no clear criteria for ‘advanced’ or optimal moment invasive therapies. is little evidence regarding upper limits levodopa doses, how these may be influenced by availability device-aided Aim: To analyze substitution therapy in patients with advanced disease. Method: In our retrospective study, we analyzed data from all hospitalized...
Abstract Continuous intra-jejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is a long-term proven and effective treatment in advanced Parkinson’s Disease (APD). Efficacy safety 16-h administration LCIG has already been established. Additional benefits 24-h have reported several case series small clinical studies. The aim this retrospective study was to compare the characteristics patients who needed from beginning DAT (device-aided treatment) with those remained standard identify...
In the advanced stages of Parkinson's disease (APD), complex forms dyskinesia may severely impair patient's quality life.In present study, we aimed to analyze evolution under LCIG therapy most important motor fluctuations and disabling dyskinesias, including diphasic dyskinesia.In this retrospective analyzed characteristics patients with APD who had at least 30 min (DID) in 3 consecutive days, were considered responders treated our clinic. Patients evaluated before after PEG 6, 12 18 months,...